Tyra Biosciences targets resistance in oncology with purpose built drugs for the benefit of patients.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/31/2021 | Series B | $106.3MM | $xx.xx | $34.84B | Alta Partners, Boxer Capital, Bvf Partners, Cannaan, Cormorant Asset Management, Janus Henderson Investors, Logos, Nextech Invest, Ra Capital | |
Price per Share
$xx.xx
Shares Outstanding
3,874,793
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alta Partners, Boxer Capital, Bvf Partners, Cannaan, Cormorant Asset Management, Janus Henderson Investors, Logos, Nextech Invest, Ra Capital
|
||||||
01/10/2020 | Series A | $51.34MM | $xx.xx | $6.85B | Alta Partners, Boxer Capital, Canaan, Ra Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
6,223,046
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alta Partners, Boxer Capital, Canaan, Ra Capital Management
|